Cue Biopharma (CUE) — Cash Flow-to-Debt Ratio
Cue Biopharma (CUE) has a Cash Flow-to-Debt Ratio of -0.49x as of September 2025, meaning its operating cash flow of $-9.02 Million could theoretically repay 0% of its total liabilities ($18.40 Million) in one year. See CUE working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cue Biopharma Cash Flow-to-Debt Ratio (2015–2024)
Historical debt coverage capacity for Cue Biopharma across 10 annual periods. Also explore Cue Biopharma (CUE) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Cue Biopharma (2015–2024)
Year-by-year debt coverage analysis for Cue Biopharma. For market capitalisation and broader financial context, see market value of Cue Biopharma.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.47x | $-36.33 Million | $14.69 Million | ▼ -51.3% |
| 2023 | -1.63x | $-39.96 Million | $24.45 Million | ▼ -0.1% |
| 2022 | -1.63x | $-41.81 Million | $25.60 Million | ▲ +24.7% |
| 2021 | -2.17x | $-38.84 Million | $17.91 Million | ▼ -37.6% |
| 2020 | -1.58x | $-32.49 Million | $20.62 Million | ▲ +12.9% |
| 2019 | -1.81x | $-30.80 Million | $17.02 Million | ▲ +22.0% |
| 2018 | -2.32x | $-26.41 Million | $11.39 Million | ▼ -1.7% |
| 2017 | -2.28x | $-12.19 Million | $5.35 Million | ▲ +57.8% |
| 2016 | -5.41x | $-5.97 Million | $1.10 Million | ▼ -22.7% |
| 2015 | -4.40x | $-1.66 Million | $376.30K | — |